ACELYRIN, INC.

Contributing Author

Recent Articles by ACELYRIN, INC.

May-13	ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases GlobeNewswire
May-06	Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote "FOR" the Proposed Transaction with Alumis GlobeNewswire
May-01	ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis GlobeNewswire